Trial Profile
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Carboplatin (Primary) ; Cibisatamab (Primary) ; Ciforadenant (Primary) ; Cobimetinib (Primary) ; Docetaxel (Primary) ; Evolocumab (Primary) ; Gemcitabine (Primary) ; Ipatasertib (Primary) ; Linagliptin (Primary) ; Pemetrexed (Primary) ; Sacituzumab govitecan (Primary) ; Tocilizumab
- Indications Carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms MORPHEUS; Morpheus Lung; MORPHEUS-NSCLC
- Sponsors Genentech; Roche
- 28 Feb 2024 According to a Repare Therapeutics media release, in October 2023, Roche also dosed the first patient in a camonsertib-based arm in its Phase 1b/2 clinical trial of multiple immunotherapy-based treatment combinations in participants with metastatic non-small cell lung cancer (Morpheus Lung; NCT03337698).
- 08 Feb 2024 Planned number of patients changed from 470 to 675.
- 08 Feb 2024 Planned End Date changed from 30 Nov 2026 to 30 Sep 2027.